BioCentury | May 27, 2020
Product Development

FDA takes on COVID-19, plus ASCO’s breakthroughs: a BioCentury podcast

The latest edition of the BioCentury This Week PODCAST covers a lot of ground -- from the new roles FDA’s Janet Woodcock and Peter Marks are taking on in the race to develop COVID-19 countermeasures,...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

Center stage at this year’s virtual ASCO meeting are a series of hot topics that demonstrate the transformative potential of a single data readout or regulatory update. Areas to watch include next-generation checkpoint targets, where...
BioCentury | Mar 25, 2020
Deals

AstraZeneca, Silence partner to bring siRNA therapies to extrahepatic tissues

Thirteen years after they first teamed up, AstraZeneca and Silence are giving their partnership another shot with a new $80 million deal to develop siRNA therapeutics targeting the liver and extrahepatic tissues. The deal is...
BioCentury | Aug 2, 2019
Product Development

Boehringer plays catch-up in NASH, dives into new modalities across the board

Although Boehringer’s recent spate of deals plug pipeline holes in fibrosis and cancer, a broader survey of the pharma’s partnering activity over the last two years shows it delving into technologies that let it jump...
BioCentury | Jul 2, 2019
Company News

Boehringer races to catch up in NASH through Yuhan deal

Boehringer is playing catch up in NASH through a preclinical deal with Yuhan that doubles its programs in the indication from one to two and marks its entry into combining therapeutic MOAs -- a strategy...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BioCentury | Jun 2, 2018
Product Development

Breaking from the herd

Behind the block of clinical studies on PD-1 and PD-L1 inhibitors, researchers are casting aside their herd mentality with a wide net of strategies to solve some of the most pressing problems in oncology, such...
BioCentury | May 25, 2018
Clinical News

MiNA reports preliminary Phase I data for liver cancer candidate

MiNA Therapeutics Ltd. (London, U.K.) reported preliminary data from 10 evaluable patients with advanced hepatocellular carcinoma (HCC) in the Phase I OUTREACH trial showing that once-weekly IV MTL-CEBPA led to one partial response with a...
BioCentury | Nov 10, 2017
Company News

Boehringer, MiNA strike NASH development deal

Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with MiNA Therapeutics Ltd. (London, U.K.) to develop therapeutics to treat fibrotic liver disease using MiNA’s small activating RNA (saRNA) technology. The partners' deal is worth up to €307...
BioCentury | Nov 8, 2017
Company News

Boehringer, MiNA strike NASH development deal

Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with MiNA Therapeutics Ltd. (London, U.K.) to develop fibrotic liver disease therapeutics based on MiNA’s small activating RNA (saRNA) technology in a deal worth up to €307 million ($355.7...
Items per page:
1 - 10 of 22
BioCentury | May 27, 2020
Product Development

FDA takes on COVID-19, plus ASCO’s breakthroughs: a BioCentury podcast

The latest edition of the BioCentury This Week PODCAST covers a lot of ground -- from the new roles FDA’s Janet Woodcock and Peter Marks are taking on in the race to develop COVID-19 countermeasures,...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

Center stage at this year’s virtual ASCO meeting are a series of hot topics that demonstrate the transformative potential of a single data readout or regulatory update. Areas to watch include next-generation checkpoint targets, where...
BioCentury | Mar 25, 2020
Deals

AstraZeneca, Silence partner to bring siRNA therapies to extrahepatic tissues

Thirteen years after they first teamed up, AstraZeneca and Silence are giving their partnership another shot with a new $80 million deal to develop siRNA therapeutics targeting the liver and extrahepatic tissues. The deal is...
BioCentury | Aug 2, 2019
Product Development

Boehringer plays catch-up in NASH, dives into new modalities across the board

Although Boehringer’s recent spate of deals plug pipeline holes in fibrosis and cancer, a broader survey of the pharma’s partnering activity over the last two years shows it delving into technologies that let it jump...
BioCentury | Jul 2, 2019
Company News

Boehringer races to catch up in NASH through Yuhan deal

Boehringer is playing catch up in NASH through a preclinical deal with Yuhan that doubles its programs in the indication from one to two and marks its entry into combining therapeutic MOAs -- a strategy...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BioCentury | Jun 2, 2018
Product Development

Breaking from the herd

Behind the block of clinical studies on PD-1 and PD-L1 inhibitors, researchers are casting aside their herd mentality with a wide net of strategies to solve some of the most pressing problems in oncology, such...
BioCentury | May 25, 2018
Clinical News

MiNA reports preliminary Phase I data for liver cancer candidate

MiNA Therapeutics Ltd. (London, U.K.) reported preliminary data from 10 evaluable patients with advanced hepatocellular carcinoma (HCC) in the Phase I OUTREACH trial showing that once-weekly IV MTL-CEBPA led to one partial response with a...
BioCentury | Nov 10, 2017
Company News

Boehringer, MiNA strike NASH development deal

Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with MiNA Therapeutics Ltd. (London, U.K.) to develop therapeutics to treat fibrotic liver disease using MiNA’s small activating RNA (saRNA) technology. The partners' deal is worth up to €307...
BioCentury | Nov 8, 2017
Company News

Boehringer, MiNA strike NASH development deal

Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with MiNA Therapeutics Ltd. (London, U.K.) to develop fibrotic liver disease therapeutics based on MiNA’s small activating RNA (saRNA) technology in a deal worth up to €307 million ($355.7...
Items per page:
1 - 10 of 22